WEDNESDAY, March 7 (HealthDay News) -- The genetic makeup of cancer cells differs significantly from country to region within a single swelling, according to new research that raises questions end for end the true potential of personalized cancer remedy.

With this treatment approach, doctors study a tumor's genetic makeup to determine that drugs would work best in a fastidious patient. But if the genetic mutations driving the cancer cells succeed widely, a single tissue sample won't indispensably give the full picture.

This "targeted therapy" involves "sticking a needle into the primeval tumor site and taking a dull sliver of a tumor, doing a gene calculus, and creating a genetic profile of the tumor to predict how the tumor command behave," explained Dr. Dan Longo, one oncologist and deputy editor at the New England Journal of Medicine.

"What this notes tells us is that is some oversimplification of the complexity of tumors and their heterogeneity," he declared. "If you look at different sites of the very same tumor and the very similar person, one site might tell you a gene outline associated with a good prognosis and the other locality will tell you a gene side view associated with a bad prognosis."

Longo wrote an editorial accompanying the new study, published in the March 8 delivery of the New England Journal of Medicine.

In the study, scientists from Cancer Research UK London Research Institute took 13 biopsies, or series samples, from a patient whose kidney cancer had ~ abroad. The biopsies were from eight regions of the kidney tumor and four tumors in the chest and lungs.

Researchers also took legitimate tissue, sequenced the patient's genome and compared that to which they found in the biopsies.

Genetic dissection turned up 128 mutations in the tumors. But solely about one-third, or about 40 of those mutations, were attentive in all of the biopsies.

"The more than half of mutations are not shared in every biopsy," said senior study author Charles Swanton, a professor of cancer remedial agent at the research institute.

Swanton and his colleagues also analyzed tumor tissue samples from not the same three patients with kidney cancer. From a whole of 30 biopsies from all four patients, 26 texture samples had mutations that were exceedingly heterogenous, or varied, from one one more.

Some advances have been made using targeted treatments. Tarceva (erlotinib) treats non-unintelligent-cell lung cancer by inhibiting epidermal increase factor receptor (EGFR) gene, and Herceptin (trastuzumab) is used to mark breast cancers that are human epidermal growing factor receptor 2 (HER-2)-over-confident.

But once cancer has metastasized, it fragments notoriously difficult to treat, Swanton declared. "We have not made huge progress in curing advanced metastatic sound tumors over the last decade, contemptuous opposition the new array of targeted therapies," he famous.

The heterogeneity of tumors is probable one reason why, he added.

The targeted drugs that labor probably target some ubiquitous, or threadbare, mutations, such as HER-2 or EGFR. "Different powers of the tumor can evolve independently," he related. "What we think is that the drugs that are laboring are hitting the mutations that are offering at every site of the sickness."

Moving forward, the key may have existence figuring out what those common mutations are and targeting drugs in that place, he added. But finding those targets exercise volition be challenging, he added. One submissive, he said, had three mutations in the corresponding; of like kind gene occurring in three regions of the original tumor. And tumor cells also bring to maturity resistance to medications.

"The level of complication is sobering in the extreme," he reported.

Dr. Len Lichtenfeld, deputy chief curative officer for the American Cancer Society, called the research "elegant, important work."

"Cancer is not right a single mass of tissue that has the identical genetic signature throughout it. There are changes that occur not above cancer as it develops, not alone at the primary tumor but in many in the body. This particular study goes to great lengths to show how that is in fact the subject of discussion," Lichtenfeld said.

Cancer is incredibly entangled, and this study adds another bed. to that complexity, he said. "As we wish learned more about cancer cells, we receive learned that as many questions considered in the state of we answer, as many questions come from those answers," he said.

More knowledge

The U.S. National Cancer Institute has greater degree of on personalized cancer care.

@yahoonews in c~tinuance Twitter, become a fan on Facebook